Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...

The phrase 'You are what you eat' derives from a pioneering French food critic who, 200 years ago, published a bestseller ...

A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...

Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms ...

s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals. The stock NMRA was on track for ...

Our goal is to facilitate collaboration ... in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program ...

Pharmacologic treatment is ... patients with alcohol use disorder, particularly those with severe alcohol use, and are more common in women than men. 22 Anxiety and depression and so-called ...